Reports

Ideas That Generate Results

1. Analyst View

2. Research Methodology

3. Double Barreled Antibodies – An Introduction

4. Double Barreled Antibodies Market Outlook to 2022
    4.1 BLINCYTO
          4.1.1 Market Potential
          4.1.2 Actual Market Size
    4.2 Removab
          4.2.1 Market Potential
          4.2.2 Actual Market Size

5. Double Barreled Antibodies Pipeline Analysis
    5.1 By Clinical Phase
    5.2 By Indication
    5.3 By Technology

6. Market Dynamics
    6.1 Drivers
          6.1.1 Rising Global Cancer Epidemics
          6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs
          6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy
          6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies
    6.2 Challenges
          6.2.1 Production Hurdles in Double Barreled Antibodies Development
          6.2.2 Regulatory Challenges

7. Current Status of Potential Double Barreled Antibodies in Pipeline
    7.1 BLINCYTO/Blinatumomab – Amgen Inc.
    7.2 ABT-122 – AbbVie Inc.
    7.3 MCLA-128 – Merus N.V.
    7.4 ALX-0761/M1095 - Ablynx
    7.5 MGD006/S80880 – MacroGenics, Inc.
    7.6 ZW25 – Zymeworks Inc.

8. Trends and Developments
    8.1 Bi-specific Antibody Application for Tumor Therapy
    8.2 Bi-specific Antibodies Development Against Myeloma
    8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics
    8.4 B-specific Antibody Development against Multiple Ebola viruses

9. Strategic Collaborations in the Double Barreled Antibody Industry

10. Competitive Assessment
      10.1 Amgen Inc.
      10.2 F. Hoffman La Roche Ltd.
      10.3 AbbVie Inc.
      10.4 OncoMed Pharmaceuticals, Inc.
      10.5 Glenmark Pharmaceuticals Limited
      10.6 Xencor, Inc.
      10.7 MacroGenics, Inc.
      10.8 Aptevo Therapeutics Inc.
      10.9 Ligand Pharmaceuticals, Inc.
      10.10 Regeneron Pharmaceuticals, Inc.
      10.11 Fresenius SE & Co. KGaA
      10.12 Merus N.V.